Longevity Medical Institute launches intranasal regenerative neurology platform

Longevity Medical Institute has introduced a new intranasal delivery system in San José del Cabo, Mexico, to move selected regenerative therapies toward the brain without a lumbar puncture. The program adds a non-invasive option for some neurological patients alongside intrathecal treatment.

Why it matters: - The new platform gives patients with selected neurological conditions a less invasive alternative to intrathecal administration. - The approach could widen access to regenerative neurological care for patients who may not be candidates for a lumbar puncture. - The program adds another delivery option in a field where getting therapies to the brain remains a major barrier.

What happened: - Longevity Medical Institute launched its Regenerative Neurological Therapy Program in San José del Cabo, Baja California Sur, Mexico, on July 23, 2026. - The program includes an advanced intranasal delivery platform designed to transport regenerative therapies toward the brain through the nasal cavity. - The institute says the platform expands its neurological program by offering a non-invasive option alongside intrathecal administration. - Dr. Kirk Sanford, founder and CEO of Longevity Medical Institute, said the new platform is intended to expand treatment personalization.

The details: - The brain’s blood-brain barrier blocks many therapeutic compounds from reaching the central nervous system. - Intrathecal delivery remains a direct route into cerebrospinal fluid, but it requires a lumbar puncture. - The intranasal system is designed to target the upper nasal cavity near the olfactory region rather than the lower nasal passages. - Research has shown that compounds delivered to that region may travel toward the brain along the olfactory and trigeminal nerve pathways. - The delivery platform uses an electronically controlled nebulizer instead of a traditional spray pump. - The nebulizer generates microscopic aerosol droplets and delivers them gradually over several minutes. - The design aims to increase contact time in the olfactory region, reduce medication loss into the throat, and improve delivery consistency. - Longevity Medical Institute uses the platform exclusively for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes, and selected therapeutic peptides. - Treatment recommendations are made after a multidisciplinary neurological evaluation that may include advanced imaging, laboratory testing, a neurological exam, and review of medical history. - The institute’s broader neurological program also includes intravenous regenerative therapies, intrathecal administration in its fully licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging, and multidisciplinary physician care. - For more information about the program, visit the institute’s announcement.

Between the lines: - The launch reflects a push to make regenerative neurology more flexible by matching delivery method to patient diagnosis and clinical findings. - The company is positioning intranasal delivery as a lower-burden option, while keeping intrathecal treatment available when a direct approach is needed. - The message also underscores a broader industry theme: clinical evidence for regenerative therapies is growing, but treatment selection still depends heavily on physician judgment and patient-specific factors. - The institute says published human research on MSCs and MSC-derived exosomes has reported encouraging safety and potential benefits across conditions including ischemic stroke, multiple sclerosis, ALS, spinal cord injury, Parkinson’s disease, Alzheimer’s disease, traumatic brain injury, cerebral palsy, and other neurodegenerative disorders. - The institute also says larger randomized trials are still needed to define which patients benefit most and how durable treatment responses may be.

What’s next: - Longevity Medical Institute expects physicians to use the new platform alongside other regenerative and diagnostic tools as part of individualized treatment planning. - The institute says regenerative neurological therapies will continue to evolve as additional clinical research clarifies safety, effectiveness, and patient selection. - The company is likely to lean on published evidence and physician-guided evaluation as it builds the program.

The bottom line: - Longevity Medical Institute is betting that a non-invasive nose-to-brain delivery system can make regenerative neurological treatment more practical for some patients without replacing intrathecal care.